Next Article in Journal
Hippo Pathway in Cancer, towards the Realization of Hippo-Targeted Therapy
Next Article in Special Issue
Reduction of Human Glioblastoma Spheroids Using Cold Atmospheric Plasma: The Combined Effect of Short- and Long-Lived Reactive Species
Previous Article in Journal
Involving the microRNA Targetome in Esophageal-Cancer Development and Behavior
 
 
Article

Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression

1
Department of Biology, Rio Piedras Campus, University of Puerto Rico, San Juan, PR 00931, USA
2
Department of Biochemistry, Medical Sciences Campus, University of Puerto Rico, San Juan, PR 00936, USA
3
Comprehensive Cancer Center, University of Puerto Rico, San Juan, PR 00935, USA
4
Department of Physiology, Medical Sciences Campus, University of Puerto Rico, San Juan, PR 00936, USA
5
Department of Pathology and Laboratory Medicine, Medical Sciences Campus, University of Puerto Rico, San Juan, PR 00936, USA
6
Anatomic Pathology Laboratory, Puerto Rico Medical Services Administration, San Juan, PR 00936, USA
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(10), 382; https://doi.org/10.3390/cancers10100382
Received: 9 August 2018 / Revised: 3 October 2018 / Accepted: 8 October 2018 / Published: 12 October 2018
(This article belongs to the Special Issue Glioblastoma: State of the Art and Future Perspectives)
Glioblastoma (GBM) is the most common and aggressive of all brain tumors, with a median survival of only 14 months after initial diagnosis. Novel therapeutic approaches are an unmet need for GBM treatment. MicroRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level. Several dysregulated miRNAs have been identified in all cancer types including GBM. In this study, we aimed to uncover the role of miR-143 in GBM cell lines, patient samples, and mouse models. Quantitative real-time RT-PCR of RNA extracted from formalin-fixed paraffin-embedded (FFPE) samples showed that the relative expression of miR-143 was higher in GBM patients compared to control individuals. Transient transfection of GBM cells with a miR-143 oligonucleotide inhibitor (miR-143-inh) resulted in reduced cell proliferation, increased apoptosis, and cell cycle arrest. SLC30A8, a glucose metabolism-related protein, was identified as a direct target of miR-143 in GBM cells. Moreover, multiple injections of GBM tumor-bearing mice with a miR-143-inh-liposomal formulation significantly reduced tumor growth compared to control mice. The reduced in vitro cell growth and in vivo tumor growth following miRNA-143 inhibition suggests that miR-143 is a potential therapeutic target for GBM therapy. View Full-Text
Keywords: glioblastoma; microRNAs; mouse model; cell proliferation glioblastoma; microRNAs; mouse model; cell proliferation
Show Figures

Figure 1

MDPI and ACS Style

Lozada-Delgado, E.L.; Grafals-Ruiz, N.; Miranda-Román, M.A.; Santana-Rivera, Y.; Valiyeva, F.; Rivera-Díaz, M.; Marcos-Martínez, M.J.; Vivas-Mejía, P.E. Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression. Cancers 2018, 10, 382. https://doi.org/10.3390/cancers10100382

AMA Style

Lozada-Delgado EL, Grafals-Ruiz N, Miranda-Román MA, Santana-Rivera Y, Valiyeva F, Rivera-Díaz M, Marcos-Martínez MJ, Vivas-Mejía PE. Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression. Cancers. 2018; 10(10):382. https://doi.org/10.3390/cancers10100382

Chicago/Turabian Style

Lozada-Delgado, Eunice L., Nilmary Grafals-Ruiz, Miguel A. Miranda-Román, Yasmarie Santana-Rivera, Fatma Valiyeva, Mónica Rivera-Díaz, María J. Marcos-Martínez, and Pablo E. Vivas-Mejía. 2018. "Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression" Cancers 10, no. 10: 382. https://doi.org/10.3390/cancers10100382

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop